Lycia Therapeutics 10% owner Venrock Healthcare Capital Partners III L.P. buys $645,000 of shares
Open market purchase reported on Form 4, filed Oct 30, 2026.
Snapshot
Venrock Healthcare Capital Partners III L.P., a holder of more than 10% of the shares of Lycia Therapeutics (LYCA), bought 25,004 shares in open market purchases between Oct 28, 2026 and Oct 30, 2026, about $645,000 at an average price of $25.78 a share, according to a Form 4 filed with the SEC on Oct 30, 2026.
- Independent Research
Market Data
| Company | 1D % | Price |
|---|---|---|
| ($LYCA) | ▼ −4.80% | 26.40 |
as of 16:00 ET · Realtime derived data
What We Know
The filing lists 5 open market purchase lines: • Oct 28, 2026: 10,570 shares at $25.23. • Oct 28, 2026: 4,430 shares at $25.97. • Oct 29, 2026: 1,000 shares at $26.33. • Oct 30, 2026: 8,804 shares at $26.27. • Oct 30, 2026: 200 shares at $26.86.
After the last purchase, the filing reports 6,850,237 shares held indirectly in that account.
Octans View
The purchases raised the holding reported in that account by about 0.4%, computed from the filed share counts. An open market purchase is made with the insider's own money at the market price, unlike option exercises or stock awards, which this brief excludes. The filing does not say why the insider bought. The filing is a joint filing with 8 related reporting persons; the purchases are counted once.
Bear Case · Room for Disagreement
Limits. Insiders must report trades within two business days; this brief covers one filing and does not net it against sales by the same person or other insiders. Prices are as filed; where a line shows a weighted average, the filing's footnotes give the range.
Method and source. Octans Research reads the structured Form 4 filed with the SEC, keeps open market purchases (code P) only, and computes the total value and the average price from the filed share counts and prices. The filed price must sit within 25% of the closing price on the trade date. The text is generated by a fixed template; no model wrote it.
Sources
- [1]SEC EDGAR — Form 4 filed by Venrock Healthcare Capital Partners III L.P. for Lycia Therapeutics, Oct 30, 2026
These are the sources this piece was drafted from. How we verify. Found an error? Tell us and we correct it in public.
10%
More on $LYCA
4 reports
Corebridge Financial 10% owner Nippon Life Insurance Co buys $8.7 million of shares
Open market purchase reported on Form 4, filed Oct 30, 2026.
Rapport Therapeutics director James Healy buys $20.4 million of shares
Open market purchase reported on Form 4, filed Oct 30, 2026.
SEC filing red flags, week of Oct 26 to 30, 2026
1 late filing notice, 1 non reliance warning, 3 auditor changes, 10 listing deficiency notices and 8 going concern warnings at companies listed on Nasdaq or the NYSE, each line matched to the filing.
Xylem director D Christian Koch buys $986,000 of shares
Open market purchase reported on Form 4, filed Oct 29, 2026.